rss
Tob Control 2004;13:190-195 doi:10.1136/tc.2003.004630
  • Research paper

The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles

  1. A R Gilbert1,*,
  2. C Pinget2,
  3. P Bovet1,*,
  4. J Cornuz1,†,
  5. C Shamlaye3,
  6. F Paccaud1
  1. 1Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland
  2. 2Institute of Health Economics and Management, University of Lausanne
  3. 3Ministry of Health, Victoria, Seychelles
  1. Correspondence to:
 A R Gilbert
 MPH, 207 Melville Loop #18, Chapel Hill, NC 27514, USA; agemail.unc.edu
  • Received 26 May 2003
  • Accepted 23 February 2004

Abstract

Objective: To examine the incremental cost effectiveness of the five first line pharmacological smoking cessation therapies in the Seychelles and other developing countries.

Design: A Markov chain cohort simulation.

Subjects: Two simulated cohorts of smokers: (1) a reference cohort given physician counselling only; (2) a treatment cohort given counselling plus cessation therapy.

Intervention: Addition of each of the five pharmacological cessation therapies to physician provided smoking cessation counselling.

Main outcome measures: Cost per life-year saved (LYS) associated with the five pharmacotherapies. Effectiveness expressed as odds ratios for quitting associated with pharmacotherapies. Costs based on the additional physician time required and retail prices of the medications.

Results: Based on prices for currently available generic medications on the global market, the incremental cost per LYS for a 45 year old in the Seychelles was US$599 for gum and $227 for bupropion. Assuming US treatment prices as a conservative estimate, the incremental cost per LYS was significantly higher, though still favourable in comparison to other common medical interventions: $3712 for nicotine gum, $1982 for nicotine patch, $4597 for nicotine spray, $4291 for nicotine inhaler, and $1324 for bupropion. Cost per LYS increased significantly upon application of higher discount rates, which may be used to reflect relatively high opportunity costs for health expenditures in developing countries with highly constrained resources and high overall mortality.

Conclusion: Pharmacological cessation therapy can be highly cost effective as compared to other common medical interventions in low mortality, middle income countries, particularly if medications can be procured at low prices.

Footnotes

  • ↵* Also Ministry of Health, Victoria, Seychelles

  • ↵† Also Department of Internal Medicine, University Hospital, Lausanne

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register hereto access the free archive of all BMJ Journals.

Don't forget to sign up for content alertsso you keep up to date with all the articles as they are published.